Ocular Therapeutix, Inc. (OCUL) News
Track canonical SquawkNews coverage tagged to OCUL, Ocular Therapeutix, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 13 indexed stories across 8 publication days and is ordered by the same first-publication timeline used by LiveCast.
L
Ocular Therapeutix and ANI Pharmaceuticals Stocks Trade Down, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after sentiment in the healthcare sector weakened, as the Centers for Medicare and Medicaid Services moved to cancel Affordable Care Act coverage for roughl
REGULATION | Sep 23, 2026, 08:42 PM UTC
L
OCUL - Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
OCUL - Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEWS | Sep 18, 2026, 11:00 AM UTC
M
Chardan reiterates Buy on Ocular Therapeutix, $23 target
Chardan Capital maintained a Buy rating on Ocular Therapeutix and set a $23.00 price target, implying 125.7% upside versus the Sep 15 close of $10.19.
EQUITY | Sep 16, 2026, 12:09 PM UTC
L
OCUL: AXPAXLI advances toward 2027 launch with robust clinical data, FDA alignment, and strong commercial plans
The session highlighted progress toward a 2027 launch for AXPAXLI, with a planned NDA submission in Q4 and strong FDA alignment. SOL-1 data showed clear superiority over EYLEA, and commercial readiness is high. Expansion
REGULATION | Sep 15, 2026, 04:21 PM UTC
L
OCUL: FDA-aligned NDA submission for a superior wet AMD therapy targeted for Q4 2024, with rapid adoption expected
The session highlighted strong FDA alignment for a single pivotal trial submission, with NDA filing targeted for Q4 2024 and a planned 2027 launch. SOL-1 data showed statistically significant superiority over EYLEA, and
REGULATION | Sep 15, 2026, 04:02 PM UTC
L
OCUL - Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
OCUL - Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
REGULATION | Sep 15, 2026, 11:00 AM UTC
L
Ocular Therapeutix to participate in September and October conferences
Ocular Therapeutix, Inc. (NASDAQ: OCUL) announced it will participate in upcoming investor and scientific conferences in September and October.
EQUITY | Sep 01, 2026, 11:08 AM UTC
L
OCUL - Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
OCUL - Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
EQUITY | Sep 01, 2026, 11:01 AM UTC
L
Ocular Therapeutix reports Nasdaq inducement grants under Rule 5635(c)(4)
Ocular Therapeutix reports inducement grants under Nasdaq Listing Rule 5635(c)(4), according to the company’s announcement.
REGULATION | Aug 13, 2026, 08:09 PM UTC
L
OCUL Ocular Therapeutix RESULTS: Q2, Q2 product REV $13.48M, Q2 EPS $-0.35
OCUL Ocular Therapeutix RESULTS: Q2, Q2 product REV $13.48M, Q2 EPS $-0.35
EARNINGS | Aug 03, 2026, 11:16 AM UTC
H
OCUL Posts Q2 DEXTENZA Revenue
OCUL reports Q2 DEXTENZA revenue of $13.5M
EQUITY | Aug 03, 2026, 11:11 AM UTC
L
OCUL - Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
OCUL - Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
EARNINGS | Aug 03, 2026, 11:00 AM UTC
L
OCUL PT Raised
OCUL price target raised to $23 at Chardan
EQUITY | Jun 25, 2026, 11:59 AM UTC